Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Glucosamine links hyperglycemia to mTORC1 activation and glucose toxicity in diabetes
Yael Riahi, Aviram Kogot-Levin, Ziv Teselpapa, Elisheva Zemelman, Fatema Gamal, Tamar Cohen, Abed Nasereddin, Idit Shiff, Ifat Abramovich, Bella Agranovich, Dana Avrahami, Liad Hinden, Erol Cerasi, Daljeet Kaur, Lihi Grinberg, Ron Piran, Joseph Tam, Ernesto Bernal-Mizrachi, Erez Dror, Gil Leibowitz
Yael Riahi, Aviram Kogot-Levin, Ziv Teselpapa, Elisheva Zemelman, Fatema Gamal, Tamar Cohen, Abed Nasereddin, Idit Shiff, Ifat Abramovich, Bella Agranovich, Dana Avrahami, Liad Hinden, Erol Cerasi, Daljeet Kaur, Lihi Grinberg, Ron Piran, Joseph Tam, Ernesto Bernal-Mizrachi, Erez Dror, Gil Leibowitz
View: Text | PDF
Research Article Cell biology Endocrinology Metabolism

Glucosamine links hyperglycemia to mTORC1 activation and glucose toxicity in diabetes

  • Text
  • PDF
Abstract

Hyperglycemia is a principal driver of β cell failure and multiple-organ complications in diabetes. Chronic exposure to hyperglycemia overstimulates mTORC1, disrupting glucose metabolism and promoting ER stress, oxidative stress, and inflammation; however, the upstream metabolic signal(s) linking glucose to mTORC1 activation remains unclear. Here, we identified glucosamine as a key metabolite connecting elevated glucose to mTORC1 signaling in pancreatic islets and kidney, both major targets of hyperglycemic damage. Using 13C6-glucose metabolic labeling in diabetic rodents treated with or without the SGLT2 inhibitor dapagliflozin or insulin, combined with targeted metabolomics and metabolic flux analysis, we found that tissue glucose concentrations strongly correlated with glucosamine. A similar correlation with plasma glucose was conserved in humans with or without type 2 diabetes, and inversely associated with β cell function. In vitro, low-dose glucosamine stimulated mTORC1 in islets and kidney proximal tubule cells in an O-GlcNAcylation–dependent manner. Broad phosphoproteomics and transcriptomics analyses in β cells showed that glucosamine activated mTORC1-regulating pathways, induced oxidative stress, ER stress, and dedifferentiation. Genetic inhibition of β cell mTORC1 via heterozygous Raptor knockout, as well as pharmacologic inhibition of the glucosamine/mTORC1 axis through SGLT2 inhibition, alleviated β cell stress, improved glycemic control, and restored β cell function. These findings identified the glucosamine/mTORC1 pathway as an important mediator of β cell and kidney dysfunction in diabetes.

Authors

Yael Riahi, Aviram Kogot-Levin, Ziv Teselpapa, Elisheva Zemelman, Fatema Gamal, Tamar Cohen, Abed Nasereddin, Idit Shiff, Ifat Abramovich, Bella Agranovich, Dana Avrahami, Liad Hinden, Erol Cerasi, Daljeet Kaur, Lihi Grinberg, Ron Piran, Joseph Tam, Ernesto Bernal-Mizrachi, Erez Dror, Gil Leibowitz

×

Figure 3

Regulation of β cell mTORC1 by glucosamine.

Options: View larger image (or click on image) Download as PowerPoint
Regulation of β cell mTORC1 by glucosamine.
Phosphoproteomics in MIN6 ce...
Phosphoproteomics in MIN6 cells treated with glucosamine (GlcN) with or without the OGT inhibitor (OGTi) ST 045849. MIN6 cells were serum starved for 2 hours and stimulated for 30 minutes with GlcN (1 mM) ± OGTi (10 μM). In the OGTi group, cells were pretreated with OGTi for 2 hours. (A) Pathway enrichment analysis is shown, with bars representing processes that have significant phosphorylation changes (n = 3 per group). Data were analyzed by Student’s t test. Blue bars denote pathways where phosphorylation is increased by GlcN and reverted by OGTi; red bars denote the opposite pattern. (B) Schematic model of the mTORC1 signaling hub summarizing key GlcN-induced phosphorylation events (red arrows) and their reversal by OGTi (green arrows). (C and D) Western blot analysis of the mTORC1 and AMPK activity in MIN6 cells (C) and mouse islets (D). Following a 2-hour starvation, cells and islets were stimulated for 30 minutes with glucose (Glc) or GlcN. One group included azaserine throughout. Blots show phosphorylated and total S6, 4EBP1, ULK1, and AMPK (C, n = 3–7 per group; D, n = 2, 200 islets per treatment were pooled from 3 mice). (E) mTORC1 activity in MIN6 cells, incubated in starvation medium for 2 hours, followed by treatment with Glc (5 mM) or GlcN (0.5 mM), ± OGTi (10 mM) (n = 3 per group). (F) snRNA-seq on cells from islets chronically treated with GlcN. MA plot and violin plots showing GlcN’s effects on the expression of mTOR-regulating genes (n = 3 per group). DEGs, differentially expressed genes. Data were analyzed by the Wilcoxon rank-sum test. ***P < 0.001. (G) MIN6 cells were incubated at LG with or without GlcN or HG for 72 hours followed by a 1-hour incubation at 2 or 20 mM glucose. Western blotting for phosphorylated and total S6, 4EBP1, ULK1, and AMPK was conducted (n = 3 per group).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts